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A B S T R A C TObjectives: To investigate the importance of accounting for potential
performance dependency when evaluating the cost-effectiveness of
two diagnostic tests used in combination. Methods: Two meta-
analysis models were fitted to estimate the diagnostic accuracy of
Wells score and Ddimer in combination. The first model assumes that
the two tests perform independently of one another; thus, two
separate meta-analyses were fitted to the Ddimer and Wells score
data and then combined. The second model allows for any perform-
ance dependency of the two tests by incorporating published data on
the accuracy of Ddimer stratified by Wells score, as well as studies of
Ddimer alone and Wells score alone. The results from the two meta-
analysis models were input into a decision model to assess the
impact that assumptions regarding performance dependency have
on the overall cost-effectiveness of the tests. Results: The results
highlight the importance of accounting for potential performance
dependency when evaluating the cost-effectiveness of diagnostic
tests used in combination. In our example, assuming the diagnosticsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.02.015
.ac.uk.
ondence to: Nicola Cooper, Department of Health Scperformance of the two tests to be independent resulted in the
strategy ‘‘Wells score moderate/high risk treated for DVT and Wells
score low risk tested further with Ddimer’’ being identified as the
most cost-effective at the £20,000 willingness-to-pay threshold (prob-
ability cost-effective 0.8). However, when performance dependency is
modeled, the most cost-effective strategies were ‘‘Ddimer alone’’ and
‘‘Wells score low/moderate risk discharged and Wells score high risk
further tested with Ddimer’’ (probability cost-effective 0.4). Conclu-
sions: When evaluating the effectiveness and cost-effectiveness of
diagnostic tests used in combination, failure to account for diagnostic
performance dependency may lead to erroneous results and non-
optimal decision making.
Keywords: conditional diagnostic accuracy, cost-effectiveness,
diagnostic tests, evidence synthesis.
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In the area of diagnostic test performance, evidence-based evalua-
tions are crucial to the decision-making process because early
diagnosis can lead to diseases being treated more successfully than
if treatment were delayed. Often evaluations are performed by
focusing on the accuracy of a single test to diagnose a particular
condition [1]; however, in routine clinical practice, a diagnosis is
usually based on the results obtained from multiple tests.
A recent review of the National Institute for Health Research
health technology assessment reports of decision models for
diagnostic tests containing meta-analysis results from 1997 to
2009 [1] found that 6 of the 14 (43%) reports included in the review
considered a combination of diagnostic tests strategy in the
economic decision modeling part of the report. In these six
reports, the accuracy of each combination of diagnostic tests
was calculated by either assuming 1) conditional independence
between tests or 2) the accuracy of the second test to be perfect
(which may be reasonable to assume in some contexts). Where
multiple tests are used for diagnosis, however, it is highly likely
that the tests will not perform independently (i.e., in the case of
two tests, the performance of the second test may differdepending on the results of the first test), and therefore it is
important to allow for this in the analysis. In fact, there is
evidence that when the assumption of dependence between
tests is ignored, this may lead to erroneous disease probability
estimates [2], which, if input into an economic decision model,
will carry forward into the cost-effectiveness analysis results.
In this article, we investigated the importance of allowing for
potential performance dependency when evaluating the cost-
effectiveness of two diagnostic tests used in combination (which
uses recent advances in meta-analysis methodology outlined in
our companion article [3]). This was assessed by observing the
impact on the cost-effectiveness results, and subsequent conclu-
sions reached, when performance dependency is first ignored and
then incorporated. The article focuses on the example of diagnos-
ing deep vein thrombosis (DVT) by using Wells score and Ddimer.Motivating Example: Ddimer and Wells Score Tests
for the Diagnosis of DVT
DVT is a blood clot in a deep vein (lower limb) that is usually
treatedwith anticoagulants. An accurate diagnosis of DVT is crucialSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
iences, University of Leicester, University Road, Leicester LE1 7RH,
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adverse events and also to reduce the impact of side effects from
anticoagulant treatment given to patients wrongly diagnosed
with DVT.
DVT may be diagnosed by reference tests such as ultrasound
and venography, which have high diagnostic accuracy, but such
tests are expensive to perform. Therefore, cheaper, quicker but
less accurate tests are often used for the diagnosis of DVT. Two of
these tests, which will be considered in this article, are Ddimer
(i.e., measures the concentration of an enzyme in the blood, the
higher the measurement the more likely DVT) and Wells score
(devised from an assessment of the clinical features of DVT such
as clinical history, symptoms, and signs [4,5]). For use in diag-
nosis, the latter test is usually categorized into low (scoreo1),
moderate (score 1 or 2), and high (score42) risk of having DVT. For
more details about the diagnostic performance data of Ddimer,
Wells score, and Ddimer given Wells score used in the analysis,
see Novielli et al. [3].
In a recent review, Goodacre et al. [6] found Ddimer and Wells
score to not be accurate enough as stand-alone diagnostic tools
but that algorithms containing both Wells score and Ddimer were
potentially valuable for diagnosis.Methods
Diagnostic Accuracy Meta-Analysis Models
To investigate the impact that the assumption of test perform-
ance dependency has on the cost-effectiveness results, two
statistical analyses were undertaken to obtain the joint diag-
nostic accuracy for Wells score and Ddimer when used in
combination.
The first analysis assumed the diagnostic performance of the
two tests to be independent and therefore used the results from
two separate meta-analyses to inform the cost-effectiveness
decision model. As diagnostic accuracy is usually measured in
terms of both sensitivity (i.e., the proportion of actual positives
that are correctly identified) and specificity (i.e., the proportion of
negatives that are correctly identified), bivariate meta-analyses
[7] (which allow for the between-study correlation of sensitivity
and specificity potentially induced through varying test thresh-
olds used in the different studies) were fitted to the Wells score
data and the Ddimer data separately.
The second analysis used the meta-analytic modeling frame-
work developed by Novielli et al. [3], to account for test perform-
ance dependency in the estimation of the diagnostic accuracy of
Wells score and Ddimer used in combination. This analysis used
a multicomponent meta-analysis framework [8] to incorporate
data from studies reporting the accuracy of Ddimer stratified by
Wells score, as well as studies of Ddimer alone and Wells score
alone. Random effects models were used with different like-
lihoods required for the different data types but linked together
through the use of shared parameters [9,10]. For more details
about the data (together with references) and the analysis, see
Novielli et al. [3].
Decision Model
The comprehensive cost-effectiveness decision model (i.e., inte-
grating the meta-analysis and decision model into a single
coherent framework [11]) for evaluating a single diagnostic test
used by Sutton et al. [12] (adapted from Goodacre et al. [6]) was
modified to allow for the incorporation of two tests in combina-
tion (Fig. 1). This decision model assumed a simplified diagnosis-
to-treatment pathway for DVT whereby patients who were
diagnosed as positive (on the basis of one of the strategiesdefined in the next section) were treated with anticoagulants,
which potentially may cause harmful side effects such as bleed-
ing at different intensities (i.e., false- and true-positive patients
may be subject to nonfatal bleeding, fatal intracranial bleeding,
nonfatal intracranial bleeding, or no bleeding when treated with
anticoagulants). The accuracy parameters (i.e., false positive,
false negative, true positive, and true negative for Wells score
and Ddimer) were informed by the meta-analysis models dis-
cussed above. All other model parameter values and sources (i.e.,
prevalence of DVT, risk of pulmonary embolism, quality of life-
adjusted life-years per each possible health status, costs, etc.) are
reported in Goodacre et al. [6].Strategies
As mentioned previously, for use in diagnosis, Wells score is
usually categorized into low (scoreo1), moderate (score 1 or 2),
and high (score42) risk of having DVT. For the analyses pre-
sented in this article, three different classifications of Wells score
were used, that is, 1) WS1—low (scoreo1) and moderate/high
(scoreZ1), 2) WS2—low/moderate (scorer2) and high
(score42), or 3) WS3—low (scoreo1), moderate (1rscorer2),
and high (score42).
In our cost-effectiveness analyses, 10 diagnostic strategies
were considered as outlined in Table 1. For each dichotomy of two
diagnostic tests, two possible strategies can be defined [13]: 1)
‘‘believe the negatives’’—only patients diagnosed as positive by
the first test received the second test (i.e., (WS1 & DD)BN and (WS2
& DD)BN) and 2) ‘‘believe the positives’’—only patients diagnosed
as negative by the first test received the second test (i.e., (WS1 &
DD)BP and (WS2 & DD)BP).
Note that for every pair of dichotomous (or dichotomized)
tests combined according to one of the strategies ‘‘believe the
negative’’ or ‘‘believe the positive,’’ the order of the tests does not
affect the diagnostic accuracy of the strategy [3] (though which
test is conditioned on may affect the estimation of effectiveness
parameters in the synthesis model) but may affect the costs
incurred. For example, Wells score is usually given first (i.e., to
everyone with suspected DVT) because it is less expensive than
Ddimer, does not require any specialist technology, and can be
carried out by an experienced doctor quickly at initial presenta-
tion. Therefore, given that Wells score is less expensive than
Ddimer, any sequence of the two tests (i.e., diagnostic strategies
1, 2, 3, and 4 listed above) where Wells score is dichotomized
and given first will be dominant from an economic point of
view compared with the same equally accurate strategy where
Ddimer is given first. Note that for strategy 8, where the first
test, Wells score, is not dichotomized, this property does not
hold.Modeling Framework
All analyses were conducted by using a comprehensive decision
modeling framework [11] that evaluates both the evidence
synthesis models and the decision model within a single
coherent framework. The modeling framework was imple-
mented by using Markov Chain Monte Carlo simulation in
WinBUGS software [14]. Noninformative (vague) prior distribu-
tions were used for all parameters estimated by the statistical
model. Graphical tools were used to assess the convergence of
the Markov Chain Monte Carlo chains, and sensitivity analyses
were performed to assess the influence of the initial values
and prior distributions on the results. The WinBUGS code
(including the specific prior distributions used) is provided in
the Appendix in Supplemental Materials found at http://dx.doi.
org/%2010.1016/j.jval.2013.02.015.
Fig. 1 – Decision tree for the economic decision model: ‘‘Believe the negatives’’ strategy (adapted from Sutton et al. [12]
to include two diagnostic tests). PE, pulmonary embolism; PTS, post-thrombotic syndrome.
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Meta-Analyses
Table 2 presents the results from the two different meta-analysis
models (i.e., independent and dependent). The results are pre-
sented in terms of the sensitivity and specificity. A good diag-
nostic strategy, in terms of diagnostic accuracy, is defined as one
in which the sensitivity is high and the specificity is high. In this
case, the strategies with the highest sensitivity and specificity are
strategy 1 (i.e., Wells score WS1 followed by Ddimer, ‘‘believe the
negatives’’) and strategy 8 (i.e., Wells score WS3) regardless of the
meta-analysis model(s) used. Note that strategies 9 and 10, in
which no diagnostic test is undertaken, result in zero specificity
and zero sensitivity, respectively.
The modeling assumptions of performance independence and
dependence of tests affect only those strategies that contain both
Wells score and Ddimer used in combination (i.e., strategies 1–4).
Comparing the sensitivity estimates for these strategies, it can be
observed that different estimates are obtained for the two
different synthesis models considered (i.e., independent ordependent), except for strategy 2 in which the mean estimates
are identical. Similar results are observed for specificity, except
for strategy 3 in which the credible intervals for the mean
estimates obtained from the two different synthesis models
overlap. For both sensitivity and specificity, it can also be
observed that the uncertainty around the estimates is greater
when the performance dependence of the tests is assumed. The
impact that these differences in sensitivity and specificity
obtained from the two different synthesis models, and their
associated uncertainty, had on the cost-effectiveness results is
reported below.
Cost-Effectiveness
The accuracy estimates reported in Table 2 were input into the
decision model to evaluate the cost-effectiveness of the 10
different diagnostic strategies outlined above. Figure 2 presents
the cost-effectiveness acceptability curves for each diagnostic
strategy by using the independent and the dependent meta-
analysis results. When the test performance of Wells score and
Ddimer was assumed to be independent, strategy 1 (i.e., Wells
score WS1 followed by Ddimer ‘‘believe the negatives’’) was
Table 1 – Description of diagnostic strategies implemented in the decision model.
Notation Summary Description
1 (WS1 & DD)BN Wells score WS1 followed by Ddimer ‘‘believe the
negatives’’
Wells score low risk: discharge
Wells score moderate/high risk: further test with
Ddimer
2 (WS1 & DD)BP Wells score WS1 followed by Ddimer ‘‘believe the
positives’’
Wells score low: further test with Ddimer
Wells score moderate/high risk: treat
3 (WS2 & DD)BN Wells score WS2 followed by Ddimer ‘‘believe the
negatives’’
Wells score low/moderate risk: discharge
Wells score high risk: further test with Ddimer
4 (WS2 & DD)BP Wells score WS2 followed by Ddimer ‘‘believe the
positives’’
Wells score low/moderate risk: further test with
Ddimer
Wells score high risk: treat
5 DD only Ddimer only Ddimer negative: discharge
Ddimer positive: treat
6 WS1 only Wells score WS1 only Wells score low risk: discharge
Wells score moderate/high risk: treat
7 WS2 only Wells score WS2 only Wells score low/moderate risk: discharge
Wells score high risk: treat
8 WS3 & DD Wells score WS3 followed by Ddimer for moderate risk
only
Wells score low risk: discharge
Wells score moderate risk: further test with Ddimer
Wells score high risk: treat
9 No test, treat all No test, treat all Treat all
10 No test, treat
none
No test, treat none Treat none
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 3 6 – 5 4 1 539identified as the most cost-effective at the £20,000 willingness-to-
pay threshold (probability cost-effective 0.8) (Fig. 2A). When this
assumption was relaxed, and diagnostic performance was
assumed to be dependent between the two tests, the most cost-
effective strategies at the £20,000 threshold were strategy 5 (i.e.,
Ddimer alone) and strategy 3 (i.e., Wells score WS2 followed by
Ddimer ‘‘believe the negatives’’) with a probability of 0.4 (Fig. 2B).
Thus, in this example, the assumption of performance depend-
ence altered the cost-effectiveness results and the conclusions
drawn.
Figure 2C presents a further set of cost-effectiveness accept-
ability curves. These are, in fact, generated by using the results
from the dependent meta-analysis (as for Fig. 2B) but here the
estimation of test performance is based on the predictive poste-
rior distribution rather than the posterior distribution for the
mean effect. Although currently this approach is not routinely
taken, there are strong arguments, in some contexts, for the use
of predictive distributions when the target population can be
viewed as a further ‘‘sample’’ from the distribution of potential
patient populations—see Ades et al. [15] for a full consideration
of this topic. In this example, using the predictive distribution did
not change the overall rankings of the front-running strategies
but the extra variability induced in the modeling results in a
diminished certainty in which strategies are considered cost-
effective. For example, when assuming diagnostic performance
dependency between the two tests and using the distribution of
mean effects, at the £20,000 threshold, Ddimer was estimated to
be the most cost-effective with a probability of 0.4; this dimin-
ished to 0.3 when predictive distributions of test performance
were used instead.Discussion and Conclusions
Traditionally, as for primary studies, systematic reviews and
meta-analysis of diagnostic test accuracy studies have focused
on the performance of individual tests despite the use of
multiple tests being commonplace in routine clinical practice.
A recent review [1] showed that where the performanceaccuracy and cost-effectiveness of multiple diagnostic tests
had been evaluated in the National Institute for Health
Research health technology assessments, the strong (and we
suspect often incorrect) assumption of independence between
tests was usually made. This is likely, at least in part, to be due
to such evaluations being informed by meta-analyses of indi-
vidual tests and also due to fewer studies reporting multiple
tests in the literature. However, our companion article [3]
outlines a methodology for combining disparate evidence to
evaluate sequences of tests while taking account of any
correlation in the performance of the tests. In this article, we
have shown the importance of allowing for test performance
dependency (utilizing the aforementioned methodology [3])
when evaluating the diagnostic accuracy, and subsequent
cost-effectiveness, of tests used in combination. The impor-
tance of modeling test dependency is brought home in the DVT
example considered here where the conclusions regarding the
most cost-effective strategy for diagnosing DVT changed com-
pared with the analysis when any such dependency is ignored.
We appreciate that no data at all may be available on depend-
ency between tests in some contexts, but we do not consider
that situation in the present article. We do believe, however,
that steps should be taken to model dependency even in the
absence of data because assuming independence is almost
certainly incorrect. This could take the form of a sensitivity
analysis exploring the impact of specifying different values for
the correlation or placing a probability distribution on the
parameter derived from related data (i.e., from other diagnostic
tests) and/or expert opinion. The latter would be necessary if
one wished to establish the value of conducting studies esti-
mating the degree of dependency via a value of information
analysis [16].
For detailed discussions of the limitations of the primary
study data, we refer the reader to our companion article [3].
Issues raised there include heterogeneity in study results and
known variable study quality, which were not accounted for in
the modeling but potentially could have been addressed through
the use of study-level covariates. There are also limitations in the
economic modeling including the restriction to the evaluation of
Table 2 – Accuracy parameter estimates for the decision model obtained from the two different meta-analysis
models.
Strategy Independent Dependent
Mean (95% CrI) Mean (95% CrI)
1. (WS1 & DD)BN Sensitivity 0.818 (0.813–0.823) 0.836 (0.830–0.840)
Specificity 0.776 (0.759–0.792) 0.697 (0.673–0.724)
2. (WS1 & DD)BP Sensitivity 0.992 (0.991–0.992) 0.992 (0.987–0.996)
Specificity 0.275 (0.258–0.290) 0.329 (0.308–0.345)
3. (WS2 & DD)BN Sensitivity 0.497 (0.497–0.497) 0.505 (0.505–0.506)
Specificity 0.948 (0.936–0.957) 0.938 (0.920–0.954)
4. (WS2 & DD)BP Sensitivity 0.968 (0.966–0.970) 0.790 (0.784–0.796)
Specificity 0.487 (0.486–0.488) 0.494 (0.492–0.494)
5. DD only Sensitivity o 0.931 (0.928–0.933) 4
Specificity o 0.553 (0.550–0.555) 4
6. WS1 only Sensitivity o 0.880 (0.872–0.887) 4
Specificity o 0.498 (0.497–0.498) 4
7. WS2 only Sensitivity o 0.534 (0.533–0.535) 4
Specificity o 0.883 (0.901–0.862) 4
8. WS3 & DD Sensitivity o 0.856 (0.849–0.862) 4
Specificity o 0.701 (0.726–0.696) 4
9. No test, treat all Sensitivity o 1.000 4
Specificity o 0.000 4
10. No test, treat none Sensitivity o 0.000 4
Specificity o 1.000 4
F
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principle both the synthesis and decision modeling could be
extended to combinations of three or more tests, we leave an
implementation of this as a topic for further work. Here, the
number of parameters in the evidence synthesis modeling would
increase sharply, and we suspect that there would usually be a
greater paucity of direct evidence evaluating three or more tests0.
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 3 6 – 5 4 1 541considered the use of the Ddimer test at the (mean) threshold
reported in the literature; that is to say, consideration was not
given to alternative operating loci along the summary receiver
operating characteristic curve estimated by the synthesis model.
Further modeling, however, could be carried out to identify the
loci on the summary receiver operating characteristic curve that
maximizes cost-effectiveness as we have described elsewhere [12].
One assumption of the cost-effective evaluation presented in
this article is that the diagnostic strategies that were evaluated
were ‘‘definitive’’; that is, they represented an exhaustive range of
diagnostic test strategies to DVT, where the diagnosis leads either
to discharge (when negative diagnostic result) or treatment
(when positive diagnostic result), and there is no further testing
before or after each strategy. This was a simplification of the
problem of diagnosing DVT to evaluate the effect of considering
or ignoring dependency between tests when performing cost-
effective evaluations. It can also be considered that there are
more tests that may be combined in a strategy for DVT (e.g.,
ultrasound and venography).
In our companion article [3], we noted that the studies
evaluating single tests had little impact on the estimates of test
performance and that this had important implications for those
designing and conducting studies of test accuracy in the future.
The impact of this observation could be sharpened and further
quantified by using value of information methods [17] in an
economic framework such as the one presented. For example,
such modeling will identify the strategies that are potentially most
cost-effective and uncertainty in the effectiveness of such strat-
egies could be reduced by the conduct of randomized controlled
trials evaluating them. Which strategies to include in a future trial
and the sample size of trial arms could both be determined by
using value of information methods within the modelling frame-
work presented here.
In conclusion, reliable clinical and economic evaluations of
appropriate/optimal use of diagnostic test pathways are chal-
lenging. Data are often far from ideal (due to studies typically
considering the performance of only individual tests rather than
multiple tests, which is often a requirement for evaluating full
diagnostic pathways), which, as we have illustrated, further com-
plicates modeling. We believe, however, that models that allow
for test dependency should routinely be used because ignoring
dependency will be naive in many contexts.Acknowledgments
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